{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:29:09Z","timestamp":1789766949964,"version":"4.0.1"},"reference-count":25,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:sec>\n<jats:title>Introduction<\/jats:title>\n<jats:p>Alcohol use disorder (AUD) is associated with significant morbidity and mortality, contributing to 5% of annual deaths. Although some literature suggests that acamprosate is an effective treatment for AUD, its traditional dosing regimen of 2 tablets 3 times daily may challenge patient adherence. This review compares clinical and pharmacokinetic data of different acamprosate dosing regimens to provide guidance on optimal dosing for treating AUD.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A comprehensive literature search was performed for articles published before March 2024. Relevant randomized controlled trials, case reports, and pharmacokinetic studies were identified from PubMed, PubMed Central, and Google Scholar.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Three dosing regimens were identified, including traditional dose, reduced dose, and reduced frequency. Definitive conclusions regarding the comparative efficacy of these regimens cannot be drawn. However, reduced doses appear safe and efficacious in small clinical trials, and a pharmacokinetic study found reduced frequency to be bioequivalent to traditional doses.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Discussion<\/jats:title>\n<jats:p>Adherence to pharmacotherapy for AUD is challenging and difficult to measure. A reduced dose regimen may be appropriate for patients who struggle with the pill burden of traditional doses, though the varying number of tablets required at different times may still pose adherence issues. The bioequivalence of reduced frequency dose to traditional dose suggests it could be a viable option for patients who find a 3-time daily frequency cumbersome. However, the lack of data on the clinical efficacy of reduced frequency makes it difficult to recommend as a primary regimen. Further research is needed to determine if either reduced dose or reduced frequency regimens could improve patient adherence compared with a traditional dose.<\/jats:p>\n<\/jats:sec>","DOI":"10.9740\/mhc.2025.04.056","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:01:21Z","timestamp":1743811281000},"page":"56-61","source":"Crossref","is-referenced-by-count":1,"title":["Review of acamprosate pharmacokinetics and dosing strategies"],"prefix":"10.9740","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3300-9892","authenticated-orcid":true,"given":"Lauren","family":"Steil","sequence":"first","affiliation":[{"name":"PGY-1 Pharmacy Resident, Denver Health & Hospital Authority, Department of Pharmacy, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8164-1608","authenticated-orcid":true,"given":"Dale","family":"Terasaki","sequence":"additional","affiliation":[{"name":"Addiction Medicine Specialist, Denver Health & Hospital Authority, Department of Behavioral Health, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1015-7809","authenticated-orcid":true,"given":"Rebecca","family":"Reiss","sequence":"additional","affiliation":[{"name":"Psychiatric Pharmacist - Clinical Specialist, Denver Health & Hospital Authority, Department of Pharmacy, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8576-4964","authenticated-orcid":true,"given":"Michael","family":"Deaney","sequence":"additional","affiliation":[{"name":"(Corresponding author) PGY-2 Infectious Diseases Pharmacy Resident, Denver Health & Hospital Authority, Department of Pharmacy, Denver, Colorado, Michael.deaney@dhha.org"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4719","reference":[{"key":"i2168-9709-15-2-56-b01","article-title":"who.int [Internet]","year":"c2024","unstructured":"who.int [Internet]. Geneva: World Health Organization; c2024 [updated 2024 Jun 28; cited 2024 Jun 15]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/alcohol"},{"key":"i2168-9709-15-2-56-b02","series-title":"National Collaborating Centre for Mental Health. Alcohol-Use Disorders: Diagnosis, Assessment and Management of Harmful Drinking and Alcohol Dependence","year":"2011","unstructured":"National Collaborating Centre for Mental Health. Alcohol-Use Disorders: Diagnosis, Assessment and Management of Harmful Drinking and Alcohol Dependence. British Psychological Society; 2011."},{"issue":"1","key":"i2168-9709-15-2-56-b03","series-title":"Am J Psychiatry","first-page":"86","article-title":"The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder","volume":"175","author":"Reus","year":"2018","unstructured":"Reus VI,Fochtmann LJ,Bukstein O, et al. The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder. Am J Psychiatry. 2018;175(1):86-90. DOI: 10.1176\/appi.ajp.2017.1750101"},{"key":"i2168-9709-15-2-56-b04","series-title":"Br J Psychiatry","first-page":"73","article-title":"Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study","volume":"171","author":"Pelc","year":"1997","unstructured":"Pelc I,Verbanck P,Le Bon O,Gavrilovic M,Lion K,Lehert P. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. Br J Psychiatry. 1997;171:73-7. DOI: 10.1192\/bjp.171.1.73"},{"issue":"2","key":"i2168-9709-15-2-56-b05","series-title":"Alcohol Alcohol","first-page":"239","article-title":"Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol","volume":"30","author":"Paille","year":"1995","unstructured":"Paille FM,Guelfi JD,Perkins AC,Royer RJ,Steru L,Parot P. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol. 1995;30(2):239-47. PMID: 7662044"},{"issue":"3","key":"i2168-9709-15-2-56-b06","series-title":"Eur Child Adolesc Psychiatry","first-page":"144","article-title":"Acamprosate and its efficacy in treating alcohol dependent adolescents","volume":"12","author":"Niederhofer","year":"2003","unstructured":"Niederhofer H,Staffen W. Acamprosate and its efficacy in treating alcohol dependent adolescents. Eur Child Adolesc Psychiatry. 2003;12(3):144-8. DOI: 10.1007\/s00787-003-0327-1"},{"key":"i2168-9709-15-2-56-b07","series-title":"Acamprosate [package insert]","year":"2004","unstructured":"Acamprosate [package insert]. St. Louis, MO. Forest Pharmaceuticals, Inc.; 2004."},{"issue":"17","key":"i2168-9709-15-2-56-b08","series-title":"JAMA","first-page":"2003","article-title":"Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial","volume":"295","author":"Anton","year":"2006","unstructured":"Anton RF,O\u2019Malley SS,Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003-17. DOI: 10.1001\/jama.295.17.2003"},{"issue":"2","key":"i2168-9709-15-2-56-b09","series-title":"PLoS One","first-page":"e0263350","article-title":"The rates and measurement of adherence to acamprosate in randomised controlled clinical trials: a systematic review","volume":"17","author":"Donoghue","year":"2022","unstructured":"Donoghue K,Hermann L,Brobbin E,Drummond C. The rates and measurement of adherence to acamprosate in randomised controlled clinical trials: a systematic review. PLoS One. 2022;17(2):e0263350. DOI: 10.1371\/journal.pone.0263350"},{"issue":"22","key":"i2168-9709-15-2-56-b10","series-title":"Health Technol Assess","first-page":"1","article-title":"Adjunctive medication management and contingency management to enhance adherence to acamprosate for alcohol dependence: the ADAM trial RCT","volume":"27","author":"Donoghue","year":"2023","unstructured":"Donoghue K,Boniface S,Brobbin E, et al. Adjunctive medication management and contingency management to enhance adherence to acamprosate for alcohol dependence: the ADAM trial RCT. Health Technol Assess. 2023;27(22):1-88. DOI: 10.3310\/DQKL6124"},{"key":"i2168-9709-15-2-56-b11","series-title":"Ther Clin Risk Manag","first-page":"45","article-title":"Acamprosate for treatment of alcohol dependence: mechanisms, efficacy, and clinical utility","volume":"8","author":"Witkiewitz","year":"2012","unstructured":"Witkiewitz K,Saville K,Hamreus K. Acamprosate for treatment of alcohol dependence: mechanisms, efficacy, and clinical utility. Ther Clin Risk Manag. 2012;8:45-53. DOI: 10.2147\/TCRM.S23184"},{"issue":"S10","key":"i2168-9709-15-2-56-b12","series-title":"Med J Aust","first-page":"S57","article-title":"The importance of spirituality in medicine and its application to clinical practice","volume":"186","author":"D\u2019Souza","year":"2007","unstructured":"D\u2019Souza R. The importance of spirituality in medicine and its application to clinical practice. Med J Aust. 2007;186(S10):S57-9. DOI: 10.5694\/j.1326-5377.2007.tb01043.x"},{"key":"i2168-9709-15-2-56-b13","series-title":"The Book of Revelation: A Commentary on the Greek Text","author":"Beale","year":"2008","unstructured":"Beale GK. The Book of Revelation: A Commentary on the Greek Text. Eerdmans; 2008."},{"issue":"6","key":"i2168-9709-15-2-56-b14","series-title":"Alcohol Alcohol","first-page":"587","article-title":"A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse","volume":"35","author":"Chick","year":"2000","unstructured":"Chick J,Anton R,Checinski K, et al. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol. 2000;35(6):587-93. DOI: 10.1093\/alcalc\/35.6.587"},{"key":"i2168-9709-15-2-56-b15","series-title":"Cerebrum","first-page":"cer-13-18","article-title":"Naltrexone: a history and future directions","volume":"2018","author":"Srivastava","year":"2018","unstructured":"Srivastava AB,Gold MS. Naltrexone: a history and future directions. Cerebrum. 2018;2018:cer-13-18. PMCID: PMC6353110"},{"key":"i2168-9709-15-2-56-b16","series-title":"Naltrexone [package insert]","year":"2013","unstructured":"Naltrexone [package insert]. Pomona, NY. Duramed Pharmaceuticals, Inc.; 2013."},{"issue":"3","key":"i2168-9709-15-2-56-b17","series-title":"Alcohol Alcohol","first-page":"251","article-title":"A comparison of two intensities of psychosocial intervention for alcohol dependent patients treated with acamprosate","volume":"39","author":"Hammarberg","year":"2004","unstructured":"Hammarberg A,Wennberg P,Beck O,Franck J. A comparison of two intensities of psychosocial intervention for alcohol dependent patients treated with acamprosate. Alcohol Alcohol. 2004;39(3):251-5. DOI: 10.1093\/alcalc\/agh056"},{"issue":"5","key":"i2168-9709-15-2-56-b18","series-title":"Clin Pharmacokinet","first-page":"331","article-title":"Clinical pharmacokinetics of acamprosate","volume":"35","author":"Saivin","year":"1998","unstructured":"Saivin S,Hulot T,Chabac S,Potgieter A,Durbin P,Houin G. Clinical pharmacokinetics of acamprosate. Clin Pharmacokinet. 1998;35(5):331-45. DOI: 10.2165\/00003088-199835050-00001"},{"key":"i2168-9709-15-2-56-b19","series-title":"Bioequivalence study for highly variable drugs: the example of acamprosate","author":"Saivin","unstructured":"Saivin S,Hulot T,Theodor R, et al. Bioequivalence study for highly variable drugs: the example of acamprosate. Pharm Res. Forthcoming."},{"issue":"11","key":"i2168-9709-15-2-56-b20","series-title":"Expert Opin Drug Discov","first-page":"1355","article-title":"The development of acamprosate as a treatment against alcohol relapse","volume":"9","author":"Kufahl","year":"2014","unstructured":"Kufahl PR,Watterson LR,Olive MF. The development of acamprosate as a treatment against alcohol relapse. Expert Opin Drug Discov. 2014;9(11):1355-69. DOI: 10.1517\/17460441.2014.960840"},{"key":"i2168-9709-15-2-56-b21","series-title":"Behav Res Ther","first-page":"11","article-title":"Experimental psychopathology paradigms for alcohol use disorders: Applications for translational research","volume":"86","author":"Bujarski","year":"2016","unstructured":"Bujarski S,Ray LA. Experimental psychopathology paradigms for alcohol use disorders: Applications for translational research. Behav Res Ther. 2016;86:11-22. DOI: 10.1016\/j.brat.2016.05.008"},{"issue":"1","key":"i2168-9709-15-2-56-b22","series-title":"Hepatology","first-page":"410","article-title":"Diagnosis and treatment of alcohol use disorder in patients with end-stage alcoholic liver disease","volume":"70","author":"Caputo","year":"2019","unstructured":"Caputo F,Domenicali M,Bernardi M. Diagnosis and treatment of alcohol use disorder in patients with end-stage alcoholic liver disease. Hepatology. 2019;70(1):410-7. DOI: 10.1002\/hep.30358"},{"issue":"3","key":"i2168-9709-15-2-56-b23","series-title":"Behav Sci (Basel)","first-page":"18","article-title":"The classification of substance use disorders: historical, contextual, and conceptual considerations","volume":"6","author":"Robinson","year":"2016","unstructured":"Robinson SM,Adinoff B. The classification of substance use disorders: historical, contextual, and conceptual considerations. Behav Sci (Basel). 2016;6(3):18. DOI: 10.3390\/bs6030018"},{"key":"i2168-9709-15-2-56-b24","series-title":"Diagnostic and statistical manual III","author":"American Psychiatric Association.","year":"1980","unstructured":"American Psychiatric Association. Diagnostic and statistical manual III. APA Press; 1980."},{"key":"i2168-9709-15-2-56-b25","series-title":"Diagnostic and statistical manual IV","author":"American Psychiatric Association.","year":"1994","unstructured":"American Psychiatric Association. Diagnostic and statistical manual IV. APA Press; 1994."}],"container-title":["Mental Health Clinician"],"original-title":[],"link":[{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/15\/2\/article-p56.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/mhc.kglmeridian.com\/downloadpdf\/journals\/mhcl\/15\/2\/article-p56.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/mhc.kglmeridian.com\/downloadpdf\/journals\/mhcl\/15\/2\/article-p56.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:01:57Z","timestamp":1744761717000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/15\/2\/article-p56.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":25,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.9740\/mhc.2025.04.056","relation":{},"ISSN":["2168-9709"],"issn-type":[{"value":"2168-9709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]}}}